| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_faf522b8b83eded745c73018576219ba |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-11 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0696
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14 |
| filingDate |
2017-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_033e6df48fbe84fb0b5d4552108e50ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1653bdaf046781e2d41a6bd63196680
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66c1b8fb63cf7a42205ae6d3fc7004df |
| publicationDate |
2017-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2017158559-A |
| titleOfInvention |
Method for producing antigen-specific T cells |
| abstract |
In a CD8 single positive cell or CD4 single positive cell obtained by redifferentiation from a human T cell having antigen specificity via an iPS cell, the same TCR gene reconstitution pattern as that of the human T cell is obtained. Providing a production method in which the frequency of appearance of T cells is extremely high. A method for producing the human CD8 single positive cell or the CD4 single positive cell having antigen specificity, wherein the iPS cell derived from the human T cell is differentiated into a CD4 / CD8 double negative cell. A step of stimulating the T cell receptor of the CD4 / CD8 double negative cell, and the CD4 / CD8 double negative cell that has stimulated the T cell receptor as a CD8 single positive cell or CD4 single positive cell. And a step of differentiating. [Selection figure] None |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020251046-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019034057-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019034027-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020027094-A1 |
| priorityDate |
2012-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |